Created by potrace 1.16, written by Peter Selinger 2001-2019beatandraise.com
Latest Financials

Filings:

CategoryDateSearch FilingsInstitutional HoldersbetaEarnings TranscriptsbetaGlobal Search

SEC Edgar

PFIZER INC

NotesSupport
aboutterms
$PFE

PFIZER INC

CIK:0000078003|SEC Filings
v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 28, 2026
Jun. 29, 2025
Jun. 28, 2026
Jun. 29, 2025
Alliance revenues $ 2,697 $ 2,273 $ 5,036 $ 4,386
Total revenues 15,034 14,653 29,484 28,367
Costs and expenses:        
Cost of sales [1] 4,092 3,778 7,640 6,624
Selling, informational and administrative expenses [1] 3,411 3,415 6,372 6,446
Research and development expenses [1] 2,809 2,482 5,299 4,685
Acquired in-process research and development expenses 16 2 153 11
Amortization of intangible assets 1,185 1,211 2,368 2,421
Restructuring charges and certain acquisition-related costs 457 (18) 557 660
Other (income)/deductions––net 3,716 739 4,577 1,692
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss) [2] (653) 3,044 2,517 5,828
Provision/(benefit) for taxes on income/(loss) (407) 141 54 (48)
Income/(loss) from continuing operations (246) 2,903 2,463 5,876
Discontinued operations––net of tax 8 25 (5) 25
Net income/(loss) before allocation to noncontrolling interests (237) 2,928 2,458 5,901
Less: Net income attributable to noncontrolling interests 10 18 19 24
Net income/(loss) attributable to Pfizer Inc. common shareholders $ (248) $ 2,910 $ 2,440 $ 5,877
Earnings/(loss) per common share––basic:        
Income /loss) from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) $ (0.04) $ 0.51 $ 0.43 $ 1.03
Discontinued operations––net of tax (in dollars per share) 0 0 0 0
Net income/(loss) attributable to Pfizer Inc. common shareholders (in dollars per share) (0.04) 0.51 0.43 1.03
Earnings/(loss) per common share––diluted:        
Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) (0.04) 0.51 0.43 1.03
Discontinued operations––net of tax (in dollars per share) 0 0 0 0
Net income/(loss) attributable to Pfizer Inc. common shareholders (in dollars per share) $ (0.04) $ 0.51 $ 0.43 $ 1.03
Weighted-average shares--basic (in shares) 5,699 5,685 5,695 5,680
Weighted-average shares--diluted (in shares) 5,699 5,706 5,733 5,708
Product [Member]        
Revenues $ 11,863 $ 11,954 $ 23,578 $ 23,248
Royalty [Member]        
Revenues $ 474 $ 426 $ 870 $ 734
[1] Exclusive of amortization of intangible assets.
[2] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). Effective in the third quarter of 2025, certain expenses for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified Selling, informational and administrative expenses of approximately $38 million in the second quarter of 2025 and $74 million in the first six months of 2025 from Other business activities to Biopharma to conform to the current period presentation.